SourceThe Next Web (TNW)•May 19, 2026Stalecollected in 45m

HistoSonics secures Taiwan approval for non-invasive tumour treatment

Read original on The Next Web (TNW)

#medtech#robotics #healthcare-aiedison-histotripsy-systemhistosonicsedison histotripsy system

A breakthrough in non-invasive robotic surgery technology expanding into the Asian healthcare market.

30-Second TL;DR

What Changed

Edison Histotripsy System approved for use in Taiwan market

Why It Matters

This approval validates the clinical viability of histotripsy in Asian markets. It sets a precedent for non-invasive, image-guided robotic surgery systems.

What To Do Next

Monitor the integration of image-guided robotic systems in medical AI workflows to identify automation opportunities in surgical planning.

Who should care:Developers & AI Engineers

Key Points

•Edison Histotripsy System approved for use in Taiwan market
•Non-invasive technology eliminates need for traditional cutting or radiation
•Strategic expansion into Asia marks a major milestone for HistoSonics

Key numbers95.5%6.8%$2.25 billion$250 million

Deep Insight

Background and context from public sources — not the original article. 45 sources cited.

Enhanced Key Takeaways

•HistoSonics' Edison Histotripsy System received US FDA De Novo clearance in October 2023 for the non-invasive destruction of liver tumors, marking the first time a focused ultrasound mechanism of action other than thermal ablation earned regulatory approval worldwide.
•The technology operates by using high-amplitude, short-pulse focused ultrasound to generate 'bubble clouds' within targeted tissue, which rapidly expand and collapse to mechanically destroy tumor cells at a cellular and sub-cellular level without using heat or making incisions.
•Clinical trials, specifically the #HOPE4LIVER trials, demonstrated a high technical success rate of 95.5% and a low complication rate of 6.8% for liver tumors, with some studies suggesting potential immune system activation against tumors not directly targeted (abscopal effect).
•HistoSonics is actively pursuing additional indications beyond liver tumors, with ongoing clinical trials for kidney tumors (HOPE4KIDNEY Trial) and pancreatic tumors (GANNON Trial), and submitted a de novo application for kidney tumors to the US FDA in May 2026.
•The company was acquired in August 2025 for $2.25 billion by a consortium of investors including K5 Global, Bezos Expeditions, and Wellington Management, followed by a $250 million financing round in October 2025 to support global expansion and new clinical indications.

Competitor Analysis

HistoSonics

Technology Type: Histotripsy (Non-thermal Focused Ultrasound)
Primary Indication (if specified): Liver tumors (approved), Kidney, Pancreas (trials)
Key Differentiator (vs. HistoSonics): Mechanical destruction via microbubbles, non-thermal, real-time visualization

Chongqing Haifu Medical Technology Co., Ltd.

Technology Type: High-Intensity Focused Ultrasound (HIFU)
Primary Indication (if specified): Benign and malignant tumors (general)
Key Differentiator (vs. HistoSonics): Primarily thermal ablation

Insightec Ltd.

Technology Type: MRI-guided HIFU
Primary Indication (if specified): Essential tremor, Parkinson's dyskinesia, prostate cancer, uterine fibroids, bone metastases
Key Differentiator (vs. HistoSonics): MRI-guided, primarily thermal ablation

EDAP TMS S.A.

Technology Type: HIFU
Primary Indication (if specified): Prostate cancer, urological tumor ablation
Key Differentiator (vs. HistoSonics): Focus on urology, uses both thermal and mechanical ablation

SonaCare Medical LLC

Technology Type: HIFU
Primary Indication (if specified): Prostate health, soft tissue treatments
Key Differentiator (vs. HistoSonics): Primarily thermal ablation, focus on prostate

Theraclion S.A.

Technology Type: HIFU
Primary Indication (if specified): Breast fibroadenomas, thyroid nodules
Key Differentiator (vs. HistoSonics): Primarily thermal ablation

Alpinion Medical Systems Co., Ltd.

Technology Type: HIFU
Primary Indication (if specified): Diagnostic and therapeutic HIFU (general)
Key Differentiator (vs. HistoSonics): Integrates advanced transducer and imaging systems, primarily thermal ablation

Company	Technology Type	Primary Indication (if specified)	Key Differentiator (vs. HistoSonics)
HistoSonics	Histotripsy (Non-thermal Focused Ultrasound)	Liver tumors (approved), Kidney, Pancreas (trials)	Mechanical destruction via microbubbles, non-thermal, real-time visualization
Chongqing Haifu Medical Technology Co., Ltd.	High-Intensity Focused Ultrasound (HIFU)	Benign and malignant tumors (general)	Primarily thermal ablation
Insightec Ltd.	MRI-guided HIFU	Essential tremor, Parkinson's dyskinesia, prostate cancer, uterine fibroids, bone metastases	MRI-guided, primarily thermal ablation
EDAP TMS S.A.	HIFU	Prostate cancer, urological tumor ablation	Focus on urology, uses both thermal and mechanical ablation
SonaCare Medical LLC	HIFU	Prostate health, soft tissue treatments	Primarily thermal ablation, focus on prostate
Theraclion S.A.	HIFU	Breast fibroadenomas, thyroid nodules	Primarily thermal ablation
Alpinion Medical Systems Co., Ltd.	HIFU	Diagnostic and therapeutic HIFU (general)	Integrates advanced transducer and imaging systems, primarily thermal ablation

Technical Deep Dive

Mechanism of Action: Histotripsy utilizes high-amplitude, very short pulses of focused ultrasound to induce controlled acoustic cavitation, creating microscopic 'bubble clouds' within the targeted tissue.
Tissue Destruction: These microbubbles rapidly expand and collapse, generating powerful mechanical forces that physically break apart and liquefy tumor cells at the cellular and sub-cellular levels.
Non-thermal and Non-ionizing: The process achieves tissue destruction mechanically, without generating heat or using ionizing radiation, thereby minimizing damage to surrounding healthy tissue.
Precision and Real-time Monitoring: The Edison System enables physicians to plan, target, treat, and monitor tumor destruction with continuous real-time visualization and control through an integrated ultrasound imaging probe.
Preservation of Structures: A key advantage is the ability of histotripsy to preserve collagenous vessels and ducts within the treatment area due to its mechanical, non-thermal nature.
Potential Immune Response: Research suggests that histotripsy may expose tumor antigens, potentially enhancing the body's immune system to recognize and attack cancer cells, including those not directly treated (abscopal effect).
System Components: The Edison System employs a treatment head housing a concave therapy transducer to generate the localized bubble cloud, and an integrated ultrasound imaging probe for continuous visualization.

Future ImplicationsAI analysis grounded in cited sources

Histotripsy will become a standard non-invasive treatment option for a broader range of cancers beyond the liver.

HistoSonics is actively pursuing FDA approvals and conducting clinical trials for kidney and pancreatic tumors, indicating a clear strategic path to expanding the technology's indications.

The non-thermal and non-ionizing nature of histotripsy will lead to improved patient outcomes and reduced side effects compared to traditional ablation methods.

By mechanically destroying tissue without heat or radiation, histotripsy minimizes damage to surrounding healthy structures, potentially leading to faster recovery times and fewer complications.

HistoSonics will significantly expand its global market presence, particularly in Asia, leveraging early clinical adoption and strategic partnerships.

The recent Taiwan approval, existing installations in Hong Kong and the UAE, and distribution agreements in Japan demonstrate a clear and aggressive strategy for market penetration in the Asian region.

Timeline

2005-XX

First invention report for histotripsy disclosed to University of Michigan's tech transfer office.

2009-XX

HistoSonics spun out of the University of Michigan.

2021-XX

Edison System received FDA Breakthrough Device Designation.

2023-10

US FDA De Novo clearance for the Edison Histotripsy System for liver tumors.

2025-08

HistoSonics acquired for $2.25 billion by an investor consortium including K5 Global, Bezos Expeditions, and Wellington Management.

2025-10

HistoSonics raises $250 million in an oversubscribed Series D funding round.

2026-05-11

HistoSonics submits a de novo application to the US FDA for the Edison Histotripsy System to treat kidney tumors.

2026-05-18

Taiwan Food and Drug Administration (TFDA) approves HistoSonics' Edison Histotripsy System.

2005-XX
First invention report for histotripsy disclosed to University of Michigan's tech transfer office.
2009-XX
HistoSonics spun out of the University of Michigan.
2021-XX
Edison System received FDA Breakthrough Device Designation.
2023-10
US FDA De Novo clearance for the Edison Histotripsy System for liver tumors.
2025-08
HistoSonics acquired for $2.25 billion by an investor consortium including K5 Global, Bezos Expeditions, and Wellington Management.
2025-10
HistoSonics raises $250 million in an oversubscribed Series D funding round.
2026-05-11
HistoSonics submits a de novo application to the US FDA for the Edison Histotripsy System to treat kidney tumors.
2026-05-18
Taiwan Food and Drug Administration (TFDA) approves HistoSonics' Edison Histotripsy System.